binding cutoff of 80% or less, meaning not all of those in the high-risk group may develop PD. We note in this regard, however, that, among PARS subjects, the high-risk group appeared to have a higher total vitamin D level, although this did not reach statistical significance; our data do not trend in the direction expected if lower vitamin D levels predispose to the development of PD. Moreover, we also repeated the analysis with a more stringent DAT cutoff of <65% age-expected norms, obtaining similar results.
Third, this is a cross-sectional study in which vitamin D levels were measured at one point in time and do not necessarily represent the chronic vitamin D status of the individual participants. Last, vitamin D supplementation status was not known, so it is possible that those in the high-risk group had higher rates of supplementation. However, neither vitamin D2 nor vitamin D3 levels differed between the groups, arguing against higher rates of supplementation in the high-risk group, given that most supplements contain only vitamin D2.
In summary, in the prediagnostic PARS cohort, some of whom are at high risk for developing PD, plasma vitamin D levels were no different in subjects at high risk for developing PD versus those who were not. There were no correlations between DAT binding and vitamin D levels. Our findings are consistent with the most recent prospective study that found no association between serum vitamin D levels and PD risk. Moreover, they do not support the hypothesis that chronic vitamin D insufficiency contributes to the pathogenesis of PD.
ABSTRACT
Background: Prospective data on cognition in prodromal Parkinson's disease are limited. The objectives of this study were to assess in prodromal PD (1) if baseline cognition predicts conversion to clinical PD, (2) if baseline dopamine transporter binding predicts longitudinal changes in cognition, and (3) if impaired olfaction predicts future cognitive decline. Methods: Prodromal participants were 136 hyposmic individuals enrolled in the Parkinson Associated Risk Study. We examined baseline neuropsychological test performance in PD converters versus nonconverters and the association between baseline dopamine transporter binding and change in cognition. An additional 73 normosmic individuals were included in analyses of the relationship between hyposmia and cognitive decline. Results: In prodromal participants, baseline cognitive scores did not significantly predict conversion, but converters performed numerically worse on 5 of the 6 cognitive domains assessed, with the greatest differences in executive function/working memory (0.68 standard deviation lower) and global cognition (0.64 standard deviation lower). Lower baseline dopamine transporter binding predicted greater future decline in processing speed/attention (P 5 0.02). Hyposmia predicted greater future decline in language (P 5 0.005) and memory (P 5 0.01) abilities. Conclusions: Given hyposmia in the general population predicts cognitive decline, the role of cognition in predicting conversion in prodromal PD needs to be assessed in large cohorts followed long-term. The dopamine system may be associated with changes in processing speed/attention in individuals at risk for PD. 1 Several lines of evidence indicate that there is an identifiable and definable phase prior to the time that motor diagnostic criteria for PD are met. These include the recognition that advanced nigral degeneration is already present at the time of motor symptoms 2, 3 and that there are several clinical, biomarker, and genetic markers that alone or in combination can accurately identify a subset of individuals who eventually meet motor criteria. 4 Prodromal PD is the phase during which sign, symptom, genotype, or biomarker findings suggest the presence of early neurodegeneration, but the individual does not yet exhibit the motor features necessary for the diagnosis of PD. Formal diagnostic criteria for prodromal PD were recently proposed. 4 Among the many clinical markers of the prodromal state, the 3 associated with the highest likelihood of future PD include rapid eye movement sleep behavior disorder (RBD), olfactory loss, and reduced dopamine transporter (DAT) binding. 4 Consistent with this, in the Parkinson Associated Risk Study (PARS) cohort, the combination of hyposmia and DAT deficit at baseline was highly predictive of conversion to PD within 4 years. 5 However, impaired cognition occurs in 20%-30% of individuals with early PD 6, 7 and has been associated with both reduced DAT binding 8 and hyposmia, 9 which also predicts a greater rate of cognitive decline at this stage. 9 The epidemiology of cognitive changes among individuals with clinical markers of the prodromal state and longitudinal changes at this stage of putative PD neuropathology is not well studied.
In a cross-sectional analysis, we recently described the presence of impaired cognition in individuals with hyposmia and DAT deficit in the PARS cohort. 10 We found that incorporating cognition into models improved prediction of DAT-binding deficit. Our objectives here were to (1) assess whether baseline cognitive performance in prodromal PD predicts future conversion to PD, (2) assess if baseline DAT binding in prodromal PD predicts future cognitive decline, and (3) assess if hyposmia predicts future cognitive decline.
Methods

Study Description
Methods for participant recruitment and assessments have been previously described. [10] [11] [12] Briefly, individuals with or without a family history of PD were targeted via mail, and assessments occurred at 16 movement disorders specialty clinics in the United States. Inclusion criteria were (1) age > 50 years (or within 10 years of age of onset of an affected PD relative) and (2) no known reason for abnormal olfaction. Exclusion criteria included (1) established diagnosis of PD or other neurodegenerative disorder, (2) history of dementia or evidence for it on examination (including Mini-Mental State Examination score < 27), and (3) evidence of parkinsonism on examination thought to be consistent with PD (as determined by the investigator). Participant enrollment was initiated in 2010, and the study is ongoing. The analyses described here include data from the first 4 years of follow-up.
Participants
A total of 303 individuals completed baseline clinical and imaging evaluations; excluded from this group were those diagnosed with PD by the investigator at the time of baseline assessment (n 5 1), conversion to
nonspecified Lewy body disease (n 5 1), no follow-up visits (n 5 22), no baseline cognitive evaluation (n 5 25), and baseline cognitive data obtained at or after their second DAT scan (n 5 39). Of the remaining 215 patients, 136 subjects were hyposmic (ie, defined here as at-risk or prodromal PD) and were included in the conversion analysis (Fig. 1) . One hundred five of the hyposmic subjects had baseline cognitive testing and a baseline DAT SPECT within 1 month of each other, along with a follow-up cognitive assessment, and were included in the analysis examining long-term cognitive change. Finally, cognitive changes in 73 normosmic subjects and 125 hyposmic subjects with at least 1 follow-up visit were compared.
Assessments
Participants underwent olfactory testing, DAT scan, clinical/motor assessments, and cognitive testing. Cognitive testing (administered annually) and other study assessments have been described in detail elsewhere 10 and are shown in Supplementary Table 1. Twenty cognitive measures were combined and used to assess the following 5 domains: executive function/working memory, verbal memory, processing speed/attention, visuospatial function, and language. Scores for each cognitive test were reversed if needed, so higher scores indicate better performance. Domain z scores and a global cognitive score based on the domain z scores were generated as previously described. 10 Normative scores were generated from the cohort of 215 participants (79 normosmics and 136 hyposmics). 10 Depression was defined as a score 16 on the Center for Epidemiological Studies Depression Scale (CES-D) 13 at study screening.
Statistical Analysis
Baseline characteristics were described using mean, standard deviation, and range or number and percent, as appropriate.
Conversion was defined as the determination by a site study investigator (movement disorders neurologist) that a participant met criteria for PD. The associations between baseline cognitive domains and conversion were investigated using separate logistic regression models adjusted for age at baseline cognitive testing, sex, depression, and education. Results are presented as odds ratios (95% confidence intervals), with the odds ratios signed so that an odds ratio > 1 implies a greater risk of conversion.
Annualized changes in cognitive domains between the baseline cognitive testing visit and the last testing visit were calculated. Their associations with baseline age-adjusted percent [
123 I]b-CIT SPECT lowest putamen:cerebellum binding ratio (hereafter referred to as DAT binding) were investigated using separate multiple regression models adjusted for age at baseline cognitive testing, sex, depression, education, and the baseline value of the cognitive domain. For ease in presentation, these adjusted models were rerun with baseline age-adjusted percent putamen dichotomized
FIG. 1. Flow diagram of prodomal participants. W E I N T R A U B E T A L
at 80%; results are presented as adjusted (leastsquares) z-score means with 95% confidence intervals. The associations of annualized changes in cognitive domains with olfactory status were investigated using the same method.
Results
Participant Characteristics
Baseline characteristics of the 136 hyposmic participants included in these analyses are shown in Supplementary Table 2 . Of the 136 hyposmic participants, 35 (26%) had DAT reduction, and 101 (74%) did not.
Association Between Baseline Cognition and
Conversion to PD During mean 6 SD 3.8 6 1.5 years (range, 1-5 years) of follow-up for the 136 individuals included in this analysis, 10 individuals converted to a clinical diagnosis of PD, 2 of whom were subjects with scans without evidence of dopaminergic deficit, who were excluded from the subsequent analyses. Baseline global cognition and all cognitive domains except language were numerically worse among converters compared with nonconverters, with the greatest differences for executive function/working memory (0.68 SD difference) and global cognition (0.64 SD difference) scores (Supplementary Table 3 ). The odds ratios for predicting conversion were 2.71 (0.97-7.57) for executive function/working memory and 2.55 (0.92-7.09) for global cognition.
Association Between Baseline DAT Binding and Longitudinal Cognitive Performance
Hyposmics in the DAT reduction group had numerically greater annualized rate of decline in global cognition, language, memory, and processing speed/ attention than those in the higher DAT group (Table 1) . In separate regression models that controlled for baseline cognitive performance, age, sex, education, and depression, lower baseline DAT binding (as a continuous measure) predicted long-term decline in processing speed/attention (P 5 0.02).
Association Between Baseline Olfaction and Longitudinal Cognitive Performance
In multiple regression models participants with hyposmia at baseline, compared with normosmics, had numerically greater future decline in global cognition and all cognitive domains except processing speed/attention, with statistically significant decline in language (P 5 0.005) and memory (P 5 0.01); see Supplementary Table 4 .
Discussion
In this study of individuals considered to be at risk, or prodromal, for PD based on being hyposmic, cognitive performance did not predict which hyposmic individuals in the general population would convert to PD. However, processing speed/attention declined more over time among those at greatest risk for PD (ie, with DAT reduction), and hyposmia was associated with future decline in language and memory abilities. In addition, although baseline cognitive performance was not a significant predictor of conversion to PD, numerical differences (ie, 0.6-0.7 SD for executive function/ working memory and global cognition) suggest that it has the potential to contribute to prediction in a larger sample followed long-term.
That hyposmics with DAT reduction had relative decline in processing speed/attention over time also supports categorizing this group of individuals as prodromal PD. Although there are few data on longitudinal cognitive changes in prodromal PD, several studies have shown multidomain cognitive changes in idiopathic RBD, 14 a disorder with almost universal long-term conversion to PD or dementia with Lewy bodies. Additionally, a study of idiopathic RBD patients found longitudinal changes in delayed verbal memory and visuospatial learning domains. 15 In addition, a recent case-control study found Significance of baseline DAT binding (continuous) on change in cognition in entire sample from separate multiple regression models adjusted for age at baseline cognitive testing, sex, education, depression, and baseline cognitive measure. that PD patients demonstrated subtle cognitive deficits up to 7 years before diagnosis compared with controls. 16 According to Braak's hypothesis, 17 an individual with hyposmia and reduced DAT binding likely has involvement of several brain areas including the olfactory bulb, medulla/pons (including involvement of norepinephrine and serotonin nuclei), and midbrain (dopaminergic neurons). Many of the latter regions and neurotransmitter systems, including dopaminergic 18 and noradrenergic 19 projections to the prefrontal cortex, mediate processing speech/attention. 18 This region also mediates executive function/working memory, and we expected, based on this and our previous cross-sectional analysis, 10 that executive function/ working memory also would have declined more rapidly in hyposmics with DAT reduction.
We recently reported in a cross-sectional analysis that baseline executive function/working memory and global cognition improve prediction of DAT deficit when added to other prodromal symptoms. 10 In regard to the predictive value of baseline cognition on risk of conversion to PD, we did not replicate this finding longitudinally. A previous study examining executive function in hyposmics also did not find that it predicted conversion. 20 However, in our study the number of PD converters was very small (n 5 8), hyposmic converters did perform approximately 0.65 SD worse on both executive function/working memory and global cognition at baseline, and hyposmics overall had greater decline over time in language and memory compared with normosmics. The trends we observed suggest that in larger cohorts followed longer (ie, with more converters) baseline cognitive performance might contribute to prediction of conversion. It would be of particular interest to examine this in individuals with additional prodromal features, such as hyposmics with DAT deficit and RBD. Unfortunately, our data set does not allow incorporation of RBD, as RBD in PARS was assessed based on bed-partner input, and this was not available for a large number of participants. 10 An aspect of the cohort that limits generalizability is the high percentage of participants with a family history of PD (35%).
In summary, in individuals at increased risk for PD on the basis of being hyposmic, the dopamine system is implicated in ongoing cognitive decline, particularly in the domain of attention/processing speed. Also, the role of baseline cognitive performance in prodromal PD in predicting future conversion to PD should be assessed in large cohorts followed long-term. Detectable cognitive changes are present in prodromal PD, in part appear to be a result of neurodegeneration of the dopamine system, and may have prognostic significance for future development of PD.
